Research Corporation Technologies β Full Portfolio
30 tracked investments Β· listed companies and verified rows first
Esperance develops targeted oncology therapeutics designed to selectively kill cancer cells, including chemotherapy-resistant cells, via a proprietary Cationic Lytic Peptide (CLYP) platform, membrane-disrupting peptides, and antibody drug conjugates.
BiotechHealthtechHouston, US
Hector Alila(Executive Officer, Director)Ross Barrett(Director)Peter Hoang(Director)Sonia Deggs(Executive Officer)Carola Leuschner(Executive Officer)
BoardJoseph Lovett(Director)in
Co-investorsLouisiana Funds
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureBiotechnology Value FundForbionLightspeed Venture PartnersTCG Crossover
NP Photonics designs and manufactures fiber-based photonics products, including narrow-linewidth single-frequency fiber lasers, high-power fiber lasers, multi-channel laser systems, fiber amplifiers, injection seeders, mid-infrared fiber sources, and ASE sources.
Advanced ManufacturingDeep TechDefense TechHardwareNew MaterialsTucson, US
Co-investorsShepherd Ventures
S2.dev builds infrastructure services and tools for developers.
Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US
Shikhar Bhushan(Co-founder and CEO)inStephen Balogh(Co-founder and CTO)inDwarak Govind Parthiban(Co-founder)inMehul ArorainCristian Caciucin
Co-investorsOrange CollectiveTranspose Platform ManagementY CombinatorAccel
seqWell develops reagents and technologies for next-generation sequencing library preparation, serving academic and institutional research clients.
BiotechDeep TechBeverly, US
Thomas Grant(Executive Officer)inDaniel Calvo(Executive Officer, Director)JoeJackJoseph Mellor(Executive Officer, Director)Joseph Mellor, Ph.D.(Executive Officer, Director)
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
AlchemiaAlerion BiomedicalAPT PharmaceuticalsAragen Bioscience, LLCArana Therapeutics, LtdBioCisionBionomicsBioVentures AustraliaCatalyst Biosciences Inc.Coronis Medical Ventures, LLCCryoFluor Therapeutics LLCCylene PharmaceuticalsDisperSol TechnologiesFullerene International CorporationKerberos Proximal Solutions Inc.Leto Medical LLCOncoGenex TechnologiesParinGenix Inc.S2 GenomicsSertoli Technologies Inc.Spirogen Ltd.Therapeutic Human Polyclonals, Inc.Valeo Medical Inc.Varix Medical Corp.VasoNova, Inc.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.